Drug Approval | September 16, 2025
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Goyal reaffirmed the government’s commitment to facilitating market access, reducing trade barriers, and ensuring that Indian exporters remain globally competitive
Subscribe To Our Newsletter & Stay Updated
